INTRODUCTION {#sec5}
============

Cystic fibrosis (CF) is a monogenic and lethal disorder that affects multiple organ systems of the body.^[@bibr1],[@bibr2]^ The Cystic Fibrosis Foundation reports that 60 000 to 70 000 people across the world suffer from CF.^[@bibr3]^ The prevalence of CF in the Middle East has been estimated to fall in the range of 1 in 2500-5000.^[@bibr4]^ Approximately 2000 known variants have been identified for the CF gene.^[@bibr5]^ Six different classes of variants are described depending on the fate of the protein coded by the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene.^[@bibr2]^ Mutations in the gene lead to altered protein synthesis, which leads to insufficient active CFTR at the cell surface. In a previous study, we showed that screening for ten common *CFTR* gene mutations can detect 80% of cases positive for a *CFTR* variant.^[@bibr4]^

*CFTR* variants in the Saudi population have been described.^[@bibr1],[@bibr2],[@bibr5]^ In this report, we present up-to-date and comprehensive data on the allele frequency of *CFTR* mutations, zygosity, morbidity and mortality patterns of the largest cystic fibrosis center in the Gulf area and the only facility that performs whole genome sequencing for *CFTR* in Saudi Arabia.

PATIENTS AND METHODS {#sec1}
====================

This study was a retrospective chart review of all CF patients referred to the CF clinic during the period from January 1998 to December 2017. CF was diagnosed based on a typical clinical picture of cough, sputum production and high sweat chloride test in two subsequent testing samples (\>60 mmol/L) by the Wescor quantitative method.^[@bibr2]^ In the study, routine evaluation of all patients included a detailed medical and family history, physical examination, laboratory investigations and *CFTR* variant testing.

Pancreatic insufficiency was diagnosed based on stool elastase measurement of \>100--200 ug/g in stool, or a 72-hour fecal fat estimation using the van de Kamer method;^[@bibr6]^ of which a positive result corresponded to a fecal fat content \>7 g/24 hours. Bronchiectasis was identified as dilated bronchi through radiological studies like chest X-rays or computed tomography (CT). The percentage of each clinical presentation is counted in reference to the total CF population. The diagnosis of cystic fibrosis-related diabetes (CFRD) was based on fasting blood glucose (FBG) levels ≥126 mg/dL (7.0 mmol/L) or 2-hour postprandial plasma glucose levels ≥200 mg/dL (11.1 mmol/L) that persisted for more than 48 hours in duration, in the absence of a steroid effect. Respiratory cultures were taken from nasopharyngeal aspirates for patients younger than 5 years of age; and from induced sputum for patients older than 5 years of age. Culture of bronchoalveolar lavage specimens were taken from 10% of our CF population.

Definition of *CFTR* genotype {#sec1-1}
-----------------------------

A detailed family history was taken to identify other family members affected with CF. A homozygous genotype was identified as two identical pathogenic *CFTR* variants. In a compound heterozygous genotype, two different pathogenic *CFTR* variants occurred in a trans configuration at two different alleles for the same chromosome. In a heterozygous genotype, one variant was identified in one allele, while the other pathogenic alleles were not identified due to the death of parents or unavailability of *CFTR* advanced detection technology at the time of *CFTR* screening. *CFTR* private mutations have only been described in 1 to 2 families.

*CFTR* allele counts for patients and families {#sec1-2}
----------------------------------------------

Multiple siblings with a homozygous *CFTR* variant within the same family are counted as having two alleles. In a compound heterozygous *CFTR* variant, each variant is counted as one mutant allele separately (i.e., multiple CF-affected siblings within the same family will be counted with each *CFTR* variant separately). The percentage of alleles for the patients is calculated as the number of affected alleles for a certain *CFTR* variant divided by the total number of alleles for whole CF population (396 patients/792 alleles). The percentage of alleles for the families is calculated as the number of families with the affected alleles for a certain *CFTR* variant divided by the total number of alleles for whole CF population (312 families/624 alleles).

Pancreatic enzyme replacement {#sec1-3}
-----------------------------

Patients with pancreatic insufficiency were placed on pancreatic enzyme according to the CF Foundation recommendation of 1000 units of lipase/kg per meal for children less than age of four and 500--2500 units of lipase/kg per meal, half of this with snacks for individuals older than 4 years of age. For dosing by fat content of meals, 500--4000 units of lipase per gram of fat ingested per day is considered to more closely mimic pancreatic enzyme secretion in response to a meal.

*CFTR* identification {#sec1-4}
---------------------

The *CFTR* gene screen methodology involves DNA Isolation, polymerase chain reaction (PCR) amplification of genomic DNA, mutational analysis, and sequencing methods.^[@bibr7]^ Genomic DNA from the patient\'s lymphocytes was used to amplify the 27 exons and flanking sequences of the *CFTR* (NM_000492.3; NP_000483.3). The PCR products were analyzed by sequencing in both the forward and reverse directions were applied according to currently recommended methods.^[@bibr8]-[@bibr10]^ Variant detection was scored using publicly available variant databases for CF such as the Cystic Fibrosis Mutation Database (*<http://www.genet.sickkids.on.ca/CFTR/Home.html>*) and The Human Gene Mutation Database -- Professional Edition. (*<http://www.hgmd.cf.ac.uk/ac/index.php>*). Both mutation databases provided an extensive repertoire of up-to-date sequence variants, deletions and insertions for the *CFTR* gene.

Ethical considerations and statistical methods {#sec1-5}
----------------------------------------------

After obtaining ethical approval by the research advisory committee, the Declaration of Helsinki, good clinical practice guidelines were followed. Data collection and data entry were supervised by the principal investigator. All data were obtained by retrospective chart review and were stored in pediatrics research unit, accessed only by the principal investigator and the assigned clinical research coordinator. Patient information was kept strictly confidential. Each patient was given a study number, and all patient data were entered in to the designated data sheet without any patient identification. The department of Biostatistics Epidemiology and Scientific Computing (BESC) carried out statistical analysis of the data. Data is descriptive using median (interquartile range), mean (standard deviation) or number (percentage).

RESULTS {#sec2}
=======

From 1 January 1998 to 1 December 2017, 396 patients had confirmed CF (312 families) and were positive for *CFTR* variants. Median age (interquartile range) was 10.2 months (4.4 months to 5.7 years) at diagnosis and 9.7 (5.4-16.5) years at follow up. Consanguinity between parents was 85%. Clinical presentations of the 396 CF patients were pancreatic insufficiency in 376 (95%), bronchiectasis in 76 (19%), meconium ileus in 39 (10%), persistent respiratory symptoms in 186 (47%), steatorrhea in 336 (85%), increased sweating in 181 (46%), abdominal pain in 114 (29%), clubbing in 51 (13%), cholestasis in 118 (30%), and CF-related diabetes in 47.4 (12%). Vitamin A, D, E and K deficiency was detected among 37% to 70% of patients, and 371 (94%) had mild to severe malnutrition. Respiratory cultures at presentation showed *Pseudomonas aeruginosa* in 237 (60%), *Staphylococcus aureus* in 122 (31%), *Haemophilus influenzae* in 83 (21%) and *Streptococcus pneumoniae* in 63 (16%).

Of the 48 *CFTR* variants identified, 283 of the 312 families (90.7%) were homozygous, 23 (7.4%) families were compound heterozygous, and 6 (1.9%) families were in heterozygous (only one allele identified; the other allele could not be detected with the present technology). Of the 48 variants identified, 42 were known variants ([**Tables 1**](#tab1){ref-type="table"} **and** [**2**](#tab2){ref-type="table"}) and 6 were novel variants ([**Table 3**](#tab3){ref-type="table"}). Among the 42 *CFTR* variants, 10 were identified as the top most common variants which were present in 243 families/471 alleles (79.2%) ([**Table 1**](#tab1){ref-type="table"}).^[@bibr11]-[@bibr25]^ The remaining 32 reported variants were found in 54 different families. Twenty-nine variants were detected at exonic locations,^[@bibr26]-[@bibr51]^ whereas only 3 variants were detected at intronic locations in the *CFTR* gene ([**Table 2**](#tab2){ref-type="table"}).^[@bibr52],[@bibr53]^ Thirty-two of 312 families (10.2%) had private mutation.

###### 

Ten most common *CFTR* mutations in the Saudi population (243 families/318 patients).

  Ref         Location        Nucleotide change   Protein change     Alive   Died   Patients (n)   Affected alleles (patient)^[a](#tab1-fn2){ref-type="table-fn"}^   Families (n)   Affected alleles (families)^[b](#tab1-fn3){ref-type="table-fn"}^   Homozygous     Heterozygous                                                     Accession no.
  ----------- --------------- ------------------- ------------------ ------- ------ -------------- ----------------------------------------------------------------- -------------- ------------------------------------------------------------------ -------------- ---------------------------------------------------------------- ---------------
  [@bibr11]   Exon 11         c.1418delG          p.Gly473GlufsX54   46      22     68             134 (17.0)                                                        50             98 (16.0)                                                          48 (95.8) Ho   2 (4.2) comp.He[\*](#tab1-fn4){ref-type="table-fn"}              rs397508205
  [@bibr15]   Exon 22         c.3700A\>G          p.Ile1234Val       38      8      46             92 (12.0)                                                         33             66 (11.0)                                                          33 (100) Ho    0.0                                                              rs75389940
  [@bibr16]   Exon 11         c.1521_1523delCTT   p.Phe508del        25      21     46             90 (11.4)                                                         34             64 (11.0)                                                          30 (88.2) Ho   2 (5.9) Comp. He [\*](#tab1-fn4){ref-type="table-fn"} and 2 He   rs113993960
  [@bibr26]   Intron 5        c.579+1G\>T         711+1G\>T          26      10     36             72 (10.0)                                                         31             62 (10.0)                                                          31 (100) Ho    0.0                                                              rs77188391
  [@bibr18]   Intron 18       c.2988+1G\>A        3120+1G\>A         22      21     43             82 (10.2)                                                         33             62 (11.0)                                                          29 (7.9) Ho    4 (12.1) Comp. He[\*](#tab1-fn4){ref-type="table-fn"}            rs75096551
  [@bibr17]   Exon 4          c.416A\>T           p.His139Leu        20      6      26             48 (6.1)                                                          20             38 (6.4)                                                           18 (90) Ho     2 (10) Comp. He[\*](#tab1-fn4){ref-type="table-fn"}              rs76371115
  [@bibr21]   Exon 14         c.1911delG          p.Gln637Hisfs      15      5      20             38 (5.0)                                                          16             30 (5.2)                                                           14 (87.5) Ho   2 (12.5) Comp. He[\*](#tab1-fn4){ref-type="table-fn"}            rs1554389296
  [@bibr22]   Exon 12         c.1647T\>G          p.Ser549Arg        9       5      14             27 (3.5)                                                          14             27 (4.5)                                                           13 (92.9) Ho   1 (7.1) Comp. He[\*](#tab1-fn4){ref-type="table-fn"}             rs121909005
  [@bibr22]   Exon 24         c.3909C\>G          p.N1303K           8       3      11             22 (3.0)                                                          7              14 (2.3)                                                           7 (100) Ho     \-                                                               
  [@bibr23]   delExon 19-21                                          7       1      8              16 (2.1)                                                          5              10 (1.6)                                                           5 (100) Ho     \-                                                               rs80034486
  **Total**                                                                         **318**        **632 (80.3**)                                                    **243**        **471 (79**)                                                       **228 Ho**     **13 Comp. He, 2 He**                                            

Data are number or number (percent) unless noted otherwise.

Number of affected alleles for a certain *CFTR* mutation divided by total number of alleles for whole CF population (396 patients/792 alleles).

Number of families with the affected alleles for a certain *CFTR* mutation divided by total number of alleles for whole CF population (312 families / 624 alleles). Families (compound heterozygous are counted twice in [**Table 1**](#tab1){ref-type="table"} and [**2**](#tab2){ref-type="table"}). Ho: homozygous, He: heterozygous.

Compound heterozygous:

Reference 11: p.Gly473GlufsX54; 1 patient with p.Asp579Gly(c.1736A\>G); Exon 13, missense mutation, and the other patient with p.K716RfsX6 (c.2147_2149delAGAinsGG); Exon 14, Indel frameshift mutation.

16-F508del; 2 patients with p.Arg709Ter(c.2125C\>T); Exon 14, nonsense mutation. The other patient had no other mutation detected with the present technology.

18-3120+1G\>A; the other associated mutations were: 2 patients with p.Gln637Hisfs (c.1911delG); Exon 14, single nucleotide deletion, 1 patient with p.H139L(c.416A\>T); Exon 4, missense mutation, and 1 patient with p.Trp1098Ter (c.3294G\>A) Exon 20, nonsense mutation.

19-p.H139L; 1 patient with p.Gly1249Glu (c.3746G\>A); Exon 23, missense mutation, and the other patient with 3120+1G\>A (c.2988+1G\>A); Intron 18; splice donor site.

21-p.Gln637Hisfs; 1 patient with 3120+1G\>A (c.2988+1G\>A); Intron 18, splice donor site. The other patient with p.Tyr849Ter(c.2547C\>A); Exon 15, nonsense mutation.

22-p.Ser549Arg; 1 patient with p.Gly542Ter(c.1624G\>T); Exon 12, nonsense mutation.

###### 

Other *CFTR* mutations in the Saudi population (54 families/61 patients).

  Reference   Location    Nucleotide change   Protein change              Mutation effect                         \#Pts   Affected alleles (patient)^[a](#tab2-fn2){ref-type="table-fn"}^   Families   Affected alleles (families)^[b](#tab2-fn3){ref-type="table-fn"}^   Zygosity                                                                      Accession No.
  ----------- ----------- ------------------- --------------------------- --------------------------------------- ------- ----------------------------------------------------------------- ---------- ------------------------------------------------------------------ ----------------------------------------------------------------------------- ---------------
  [@bibr17]   Exon19      c.3529A\>T          p.Lys1177Ter                Nonsense                                5       10 (1.3)                                                          4          8 (1.3)                                                            4 (100) Ho                                                                    rs397508578
  [@bibr48]   Exon.21     c.3419T\>A          p.Met1140Lys                Missense                                4       8 (1.0)                                                           4          8 (1.3)                                                            4 (100) Ho                                                                    rs397508558
  [@bibr37]   Exon 12     c.1657C\>T          p.Arg553Ter                 Missense                                3       6 (1.0)                                                           3          6 (1.0)                                                            3 (100) Ho                                                                    rs74597325
  [@bibr34]   Exon 11     c.1399C\>T          p.Leu467Phe                 Missense                                3       8 (1.0)                                                           3          6 (1.0)                                                            3 (100) Ho                                                                    rs1800089
  [@bibr50]   Exon 10     c.1375_1383del9     pSer459_Gly461del           Deletion                                5       10 (1.3)                                                          3          6 (1.0)                                                            3 (100) Ho                                                                    rs786205658
  [@bibr38]   Exon 13     c.1736A\>G          p.Asp579Gly                 Missense                                4       5 (0.6)                                                           4          5 (0.82)                                                           1 (25) Ho, 2 (50) He and 1 (25) Comp He[\*](#tab2-fn5){ref-type="table-fn"}   rs397508288
  [@bibr31]   Exon 24     c.3889dupT          p.Ser1297Phefs              SNDel                                   3       6 (0.8)                                                           2          4 (0.7)                                                            2 (100) Ho                                                                    rs121908808
  [@bibr44]   exon15      c.2551C\>T          p.Arg851Ter                 Nonsense                                2       4 (0.6)                                                           2          4 (0.7)                                                            2 (100) Ho                                                                    rs121909012
  [@bibr42]   Exon14      c.2421A\>G          p.Ile807Met                 Missense                                3       6 (0.8)                                                           2          4 (0.7)                                                            2 (100) Ho                                                                    rs1800103
  [@bibr28]   Exon 4      c.443T\>C           p.Ile148Thr                 Missense                                2       4 (0.6)                                                           2          4 (0.7)                                                            2 (100) Ho                                                                    rs35516286
  [@bibr52]   Intron 2    IVS2+12T\>C         c.164+12T\>C                Splice Donor-Site                       2       4 (0.6)                                                           2          4 (0.7)                                                            2 (100) Ho                                                                    rs121908790
  [@bibr49]   Exon 23     c.3746G\>A          p.Gly1249Glu                Missense                                2       2 (0.3)                                                           2          2 (0.33)                                                           1 (50) He and 1 (50) Comp He[\*](#tab2-fn5){ref-type="table-fn"}              rs121909040
  [@bibr45]   Exon22      c.3472C\>T          p.Arg1158Ter                Nonsense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs79850223
  [@bibr47]   exon 7-19                       Large deletionc exon 7-19   \-                                      1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    
  [@bibr54]   Intron 16   IVS16 + 5G\>Ac      c.2657+5G\>A                Consensus Splice Site (Exon skipping)   1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs80224560
  [@bibr43]   Exon 15     c.2547C\>A          p.Tyr849Ter                 Nonsense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs397508394
  [@bibr40]   Exon 14     c.2125C\>T          p.Arg709Ter                 Nonsense                                3       3 (0.4)                                                           2          2 (0.33)                                                           2 (100) Comp He [\*](#tab2-fn5){ref-type="table-fn"}                          rs121908760
  [@bibr27]   exon14      c.2215delG          p.Val739Tyrfs               Frameshift                              1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs397508353
  [@bibr39]   Exon 13     c.1697C\>A          p.Ala566Asp                 Missense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs1375786834
  [@bibr55]   Exon11      c.1597T\>C          p.Phe533Leu                 Missense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs397508238
  [@bibr35]   Exon 11     c.1516A\>G          p.Ile506Val                 Missense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs1800091
  [@bibr19]   Exon 8      c.920G\>A           p.Ser307Asn                 Missense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs397508817
  [@bibr31]   Exon 7      c.853A\>T           p.Ile285Phe                 Missense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs151073129
  [@bibr26]   Exon 5      c.532G\>A           p.Gly178Arg                 Missense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs80282562
  [@bibr30]   Exon 4      c.422C\>A           p.Ala141Asp                 Missense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs397508700
  [@bibr27]   Exon 4                          G115Xc                      Nonsense                                1       2 (0.3)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    
  [@bibr25]   Exon 3      c.202A\>G           p.Lys68Glu                  Missense                                2       4 (0.6)                                                           1          2 (0.33)                                                           1 (100) Ho                                                                    rs397508332
  [@bibr47]   Exon 20     c.3294G\>A          p.Trp1098Ter                Nonsense                                1       1 (0.14)                                                          1          2 (0.33)                                                           1 (100) Comp He [\*](#tab2-fn5){ref-type="table-fn"}                          rs397508533
  [@bibr22]   Exon 12     c.1624G\>T          p.Gly542Ter                 Nonsense                                1       1 (0.14)                                                          1          1 (0.2)                                                            1 (100) Comp He [\*](#tab2-fn5){ref-type="table-fn"}                          rs113993959
  [@bibr53]   Intron 5    IVS5-1G\>Tc         c.580-1G\>T;                Splice Donor-Site                       1       1 (0.14)                                                          1          1 (0.2)                                                            1 (100) Comp He[\*](#tab2-fn5){ref-type="table-fn"}                           rs121908793
  [@bibr55]   Exon 4      425del 42 exon4     425del 42c exon4            Inframe Deletion                        1       1 (0.14)                                                          1          1 (0.2)                                                            1 (100) He                                                                    
  [@bibr26]   Exon 3      c.254G\>A           p.Gly85Glu                  Inframe deletion                        1       1 (0.14)                                                          1          1 (0.2)                                                            1 (100) Comp He [\*](#tab2-fn5){ref-type="table-fn"}                          rs75961395
                                                                                                                  61      111 (15.4)                                                        54         96 (16.2)                                                          42 Ho 4 He 8 Comp He                                                          

Data are number or number (percent) unless noted otherwise

Number of affected alleles for a certain *CFTR* mutation divided by total number of alleles for whole CF population (396 patients/792 alleles).

Number of families with the affected alleles for a certain *CFTR* mutation divided by total number of alleles for whole CF population (312 families / 624 alleles).

Private mutation. Families (compound heterozygous are counted twice in [**Table 1**](#tab1){ref-type="table"} and [**2**](#tab2){ref-type="table"}). Ho: Homozygous, He: heterozygous.

Compound heterozygous:

Reference 38: p.Asp579Gly; the other associated mutation is p.Gly473GlufsX54 (c.1418delG); Exon 11, frameshift deletion

Reference 48: p.Gly1249Glu; the other associated mutation is p.H139L (c.416A\>T) Exon 4, Missense mutation 40

Reference 40: p.Arg709Ter; the other associated mutation is F508del (c.1521_1523delCTT); Exon 11, inframe deletion

Reference 47: p.Trp1098Ter; the other associated mutation is 3120+1G\>A (c.2988+1G\>A); Intron 18; splice donor site

Reference 22: p.Gly542Ter; the other associated mutation is p.Ser549Arg (c.1645A\>C); Exon 12, missense mutation

Reference 26: c.254G\>A; the other associated mutation is F508del (c.1521_1523delCTT); Exon 11, inframe deletion

Novel Mutations {#sec2-1}
---------------

Six novel variants were found in 15/312 families (4.6%) that constituted 28 alleles ([**Table 3**](#tab3){ref-type="table"}):

1.  The variant allele, DS459_G461 (predicted deleterious due to in-frame deletion); Exon 10 was found in 4/312 families (8 alleles, 1.3%). The most common presentations included: bronchiectasis 3/4 (60%), *P aeruginosa* colonization (60%), and pancreatic insufficiency (40%).

2.  The variant allele, c.2739T\>G (p.Y913X) (predicted deleterious due to premature translation termination); Exon 17 was found in 3/312 families (6 alleles 1.0%). The clinical presentations included: echogenic liver parenchyma and mild cholestasis on ultrasonographic imaging study.

3.  The variant allele, c.2147_2149delAGAinsGG (p.K716RfsX6) (predicted deleterious due to premature translation termination); Exon 144 was found in 3/312 families (5 alleles, 0.8%). The most common presentation included: respiratory colonization (100%) with *P aeruginosa* (100%) and *S aureus/H influenza* (50%).

4.  The variant allele, c.3140-10T\>G (IVS19-10T\>G) (suspected consensus splice acceptor site mutation); Intron^[@bibr13]^ was found in 2/312 families (4 alleles 0.7%). One patient had CFRD (33%), and another patient had bilateral sequential lung transplant, chronic pancreatitis, *Aspergillus niger* pneumonia, acute rejection with severe bronchiolitis obliterans and died. The most common presentation included bronchiectasis (66.6%).

5.  The variant allele, c.3542C\>G (p.P1181R) (predicted deleterious in silico); Exon 22 was found in 2/312 families (3 alleles, 0.5%). Clinical presentations included lipodystrophy, high liver enzymes, speech and cognitive function delay, mild persistent asthma, night sweats, obstructive sleep apnea, large adenoids and tonsils, and nephromegaly.

6.  T he variant allele, c.2619G\>C (p.E873D) (predicted deleterious in silico); Exon 15^[@bibr6]^ was found in 1/312 family (2 alleles 0.3%). The clinical presentations included recurrent chest infections and failure to thrive.

###### 

Novel *CFTR* mutations in the Saudi population in this study (15 families/17 patients).

  Location    Mutation       Nucleotide change        Mutation effect                           Alive   Died   Patients (n)   Affected alleles (patient)^[a](#tab3-fn2){ref-type="table-fn"}^   Families (n)   Affected alleles (families)^[b](#tab3-fn3){ref-type="table-fn"}^   Zygosity
  ----------- -------------- ------------------------ ----------------------------------------- ------- ------ -------------- ----------------------------------------------------------------- -------------- ------------------------------------------------------------------ ----------------------------------------------------------
  Exon 10     DS459_G461     c.1375_1383del9          Inframe mutation                          4       1      5              10 (1.3)                                                          4              8 (1.3)                                                            4 (100) Ho
  Exon 17     p.Y913X        c.2739T\>G               Nonsense mutation                         3       0      3              6 (0.8)                                                           3              6 (1.0)                                                            3(100) Ho
  Exon 14     p.K716RfsX6    c.2147_2149delAGAinsGG   Indel Framshift Mutation                  2       1      3              5 (0.7)                                                           3              5 (0.82)                                                           2 (66.6) Ho 1 (33.3)[\*](#tab3-fn5){ref-type="table-fn"}
  Intron 19   IVS19-10T\>G   c.3140-10T\>G            Consensus Splice Acceptor-Site mutation   3       0      3              6 (0.8)                                                           2              4 (0.7)                                                            2 (100) Ho
  Exon 22     p.P1181R       c.3542C\>G               Missense mutation                         2       0      2              3 (0.4)                                                           2              3 (0.68)                                                           1 (50) Ho, 1 (50)[\*](#tab3-fn5){ref-type="table-fn"}
  Exon 15     p.E873Dc       c.2619G\>C               Missense mutation                         1       0      1              2 (0.3)                                                           1              2 (0.3)                                                            1 (100) Ho
  **Total**                                                                                                    **17**         **32 (4.3**)                                                      **15**         **28 (4.8**)                                                       **13 Ho, 2[\*](#tab3-fn5){ref-type="table-fn"}**

Data are number or number (percent) unless noted otherwise.

Number of affected alleles for a certain *CFTR* mutation divided by total number of alleles for whole CF population (396 patients/792 alleles).

Number of families with the affected alleles for a certain *CFTR* mutation divided by total number of alleles for whole CF population (312 families/624 alleles).

Private mutation. Families (compound heterozygous are counted twice in [**Table 1**](#tab1){ref-type="table"} and [**2**](#tab2){ref-type="table"}). Ho: Homozygous, He: heterozygous.

Compound heterozygous:

Raw \#3, Exon 14: p.K716RfsX6; the other associated mutation is p.G473EfsX54 (c.1418delG); Exon 11, inframe deletion

Raw \#5, Exon 22: p.P1181R; the other associated mutation is (p.R1162Q) (c.3485G\>A); Exon 22, missense mutation

Survival and mortality rate {#sec2-2}
---------------------------

In our study, 378 (95.5%) survived, and 18 (4.5%) died. The median survival was 20 years (75% of those diagnosed in this study lived to a mean of 17 years. In comparison to the North American data, the median age of survival in Canada was 50.9 years (95% CI: 50.5-52.2) and in the United States the median age of sujrvival was 40.6 (95% CI: 39.1-41.8) years respectively).^[@bibr54]^ There was no significant difference between males and females (*P*=.245).

DISCUSSION {#sec3}
==========

The most common *CFTR* variant in the Western world is F508del, which is found in approximately 66-75% of CF population.^[@bibr56]^ In the Saudi population there is no single common variant but 10 different variants constitute 79% of the total *CFTR* variants. We believe that the high rates of familial intermarriages among carriers of these variants have perpetuated certain *CFTR* variants. Consanguinity between parents in our CF population was 85% compared to 50% overall consanguinity in Saudi Arabia. We believe that CF has become a common disease in our population due to the consanguinity phenomenon despite being an orphan disease in other parts of the world.

The variant allele, c.1418delG (p.Gly473GlufsX54),^[@bibr13],[@bibr55],[@bibr57]^ c.416A\>T (p.His139Leu) 2 and c.579+1G\>A (711+1G\>T) 2 were first described in Saudi Arabia as novel variants, and were of native Saudi descent, and all showed symptoms early in life with severe lung disease and pancreatic insufficiency.

The variant c.1521_1523delCTT (F508del) is the most common variant in North America and Western Europe, accounting for 60-75% of all CF patients.^[@bibr13],[@bibr15],[@bibr54]^ These variants only constituted 11% of variants in the Saudi CF population, and had a milder pulmonary disease compared to other Saudi-specific CF variants.

The variant c.3700A\>G (p.Ile1234Val) is mainly described in an extended Saudi native tribe who resides around the Arabian Gulf area and travels frequently between all Gulf countries with high frequency of consanguinity. The variant has been reported in 35 patients from Qatar (which constituted 95% of their total *CFTR* mutations).^[@bibr58]^ The Qatari family is the same extended family tribe that has been reported from Saudi Arabia and carries a good prognosis. This variant was first described in Southern France in 1992.^[@bibr14],[@bibr15]^

The variant c.1647T\>G (p.Ser549Arg) was reported in native United Arab Emirates and Omani patients in more than 50% of the CF patients with severe lung disease, early *Pseudomonas aeruginosa* colonization and early death.^[@bibr59]-[@bibr62]^ whereas the variant c.1911delG (p.Gln637Hisfs) was reported in 31% 73 of CF patients in Bahrain. The proximity of Saudi Arabia, UAE and Bahrain allowed members of the same tribal origin to move freely between Gulf countries and intermarriages occur between similar tribes.

The variant allele, c.2988+1G\>A (3120+1G\>A) has been studied well by Dörk et al,^[@bibr63]^ who indicated a common origin of this variant. He analyzed DNA samples from 17 unrelated CF families from 4 different populations (Arabic, Greek, Native African, and African-American) and found a common origin of this variant. His impression was that a common ancestor had evolved separately in the respective population.

In our report, we have shown that the top 10 most common variants identified (79.2% of our CF population) could be used as a screening panel for newly diagnosed CF patients in our population that could also be applied to the rest of the Arab countries. We have also shown that a significant number of our *CFTR* variants are private mutations (20 variants in 20 families). Even though private mutations were only present in 20 families, they accounted for 41.7% of all variants encountered in the study. This is a clear reflection of the power of consanguinity to render homozygous many pathogenic alleles and is consistent with our previous experience of tremendous allelic heterogeneity that characterizes recessive disorders in our consanguineous population.^[@bibr64]^ For these reasons, special attention should be taken for *CFTR* screening of such patients in our community, and proper family counseling should be applied. Physicians in the Western countries who receive Arab patients traveling abroad for *CFTR* variant identification should consider using our screening panel rather than the Western prepared panel for *CFTR* variants. Novel variants in our population were mainly in a homozygous state and of severe clinical presentation. There was a big difference in median survival between our CF population (20 years) and North American population (from 50.9 to 40.6 years). This could be explained by the delay in diagnosis, early colonization with *P aeruginosa,* poor compliance to medications and poor nutritional status.^[@bibr54]^

In conclusion, there is a high allelic heterogeneity that characterizes *CFTR* mutational patterns in our CF population, with at least 10 common mutations that accounted for 79.2% of all *CFTR* mutations due to the spread of the variant in different tribes despite intermarriages between relatives of certain tribes. There is a high prevalence of homozygous variants, which reflects the power of consanguinity within the same tribe. Efforts must be made to improve the prognosis of this debilitating disease using preventative methods, early identification and referral to specialized centers.
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